Status:
UNKNOWN
Precision Medicine Platform for Novel Oral Anticoagulants
Lead Sponsor:
Kaohsiung Medical University
Conditions:
Anticoagulant Adverse Reaction
Eligibility:
All Genders
20+ years
Brief Summary
The anticoagulants have been developed with new generation for FDA-approved indications including treatment and prevention of venous, pulmonary, and systemic thromboembolism. While the prescription of...
Detailed Description
Pharmaceutical companies have developed new oral anticoagulants (NOACs) to replace warfarin for prevention of systemic thrombo-embolization and embolic stroke in patients with atrial fibrillation or o...
Eligibility Criteria
Inclusion
- Long-term indication for use of dabigatran
- Long-term indication for use of rivaroxaban
- Long-term indication for use of apixaban
- Long-term indication for use of edoxaban
Exclusion
- Any contraindication for use of anticoagulants
- Prisoners
- pregnancy
- mental disorders
- history of any mechanical or prosthetic valve replacement
- hemodialysis or other renal replacement therapy
- congenital coagulation abnormalities
- autoimmune diseases
Key Trial Info
Start Date :
January 2 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2022
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT04056143
Start Date
January 2 2019
End Date
December 31 2022
Last Update
September 2 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kaohsiung Medical University Hospital
Kaohsiung City, Taiwan, 807